


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented): A compound according to formula I



I


in which

D is absent or

is a saturated, fully or partially unsaturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O and/or 1 or 2 S atoms, but where at most up to 3 carbon atoms are replaced and where, in addition, the alkylene chain and/or a nitrogen present therein may be monosubstituted, disubstituted or trisubstituted by Hal, A, $-\text{[C(R}^3\text{)}_2\text{]}_n\text{-Ar}$, $-\text{[C(R}^3\text{)}_2\text{]}_n\text{-Het}$, $-\text{[C(R}^3\text{)}_2\text{]}_n\text{-cycloalkyl}$, OR^2 , $\text{N(R}^2\text{)}_2$, NO_2 , CN , COOR^2 , $\text{CON(R}^2\text{)}_2$, NR^2COA , $\text{NR}^2\text{SO}_2\text{A}$, COR^2 , SO_2NR^2 and/or $\text{S(O)}_m\text{A}$, and where, furthermore, one CH_2 group in the alkylene chain may also be replaced by a C=O group,

M is a phenyl ring or an aromatic heterocyclic ring, which may contain 1-2 N, O and/or S atoms,

R^1 and $\text{R}^{1'}$ are each, independently of one another, H, Hal, A, OR^2 , $\text{N(R}^2\text{)}_2$, NO_2 , CN , COOR^2 , $\text{CON(R}^2\text{)}_2$, $\text{C(=S)N(R}^2\text{)}_2$, $-\text{[C(R}^3\text{)}_2\text{]}_n\text{-Ar}$, $-\text{[C(R}^3\text{)}_2\text{]}_n\text{-Het}$, $-\text{[C(R}^3\text{)}_2\text{]}_n\text{-cycloalkyl}$, $-\text{[C(R}^3\text{)}_2\text{]}_n\text{-N(R}^3\text{)}_2$, CN , $-\text{C(=NH)-NH}_2$ which is unsubstituted or monosubstituted by C(=O)R^3 , COOR^3 , OR^3 , OCOR^3 , OCOOR^3 or by a conventional amino-protecting group, or



R^2 is H, A, $-[C(R^3)_2]_n$ -Ar, $-[C(R^3)_2]_n$ -Het, $-[C(R^3)_2]_n$ -cycloalkyl, $-[C(R^3)_2]_n$ -N(R^3)₂ or $-[C(R^3)_2]_n$ -OR³,

$R^{2'}$ is H, A, $-[C(R^3)_2]_n$ -Ar', $-[C(R^3)_2]_n$ -Het', $-[C(R^3)_2]_n$ -cycloalkyl, $-[C(R^3)_2]_n$ -N(R^3)₂ or $-[C(R^3)_2]_n$ -OR³,

$R^{2''}$ is H, A, $-[C(R^3)_2]_n$ -Ar', $-[C(R^3)_2]_n$ -cycloalkyl, $-[C(R^3)_2]_n$ -N(R^3)₂ or $-[C(R^3)_2]_n$ -OR³,

R^3 is H or A,

W is a monocyclic or bicyclic saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having from 1 to 4 N, O and/or S atoms, which may be monosubstituted or disubstituted by R^2 ,

X is CONR², CONR²C(R^3)₂, $-C(R^3)_2NR^2$, $-C(R^3)_2NR^2C(R^3)_2$, $-C(R^3)_2O$ -, $-C(R^3)_2OC(R^3)_2$ - or NR²CO,

Y is alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T is a monocyclic or bicyclic, saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having from 1 to 4 N, O and/or S atoms which is monosubstituted or disubstituted by =S, =NR², =N-CN, =N-NO₂, =NOR², =NCOR², =NCOOR² or =NOCOR² and may furthermore be monosubstituted, disubstituted or trisubstituted by Hal, A, $-[C(R^3)_2]_n$ -Ar, $-[C(R^3)_2]_n$ -Het, $-[C(R^3)_2]_n$ -cycloalkyl, OR³, N(R^3)₂, NO₂, CN, COOR², CON(R^2)₂, NR²COA, NR²CON(R^2)₂, NR²SO₂A, COR², SO₂NR² and/or S(O)_mA,

A is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by -CH=CH- groups, and/or in addition 1-7 H atoms may be replaced by F,

Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR³, N(R^3)₂, NO₂, CN, COOR³, CON(R^3)₂, NR³COA, NR³CON(R^3)₂, NR³SO₂A, COR³, SO₂N(R^3)₂, S(O)_mA, $-[C(R^3)_2]_n$ -COOR² or -O-[$C(R^3)_2$]_o-COOR²,

Ar' is phenyl or benzyl, each of which is unsubstituted or monosubstituted or disubstituted by Hal,

Het is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or monosubstituted, disubstituted or trisubstituted by carbonyl oxygen, =S, =N(R^3)₂, Hal, A, $-[C(R^3)_2]_n$ -Ar,

-[C(R³)₂]_n-Het¹, -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-OR², -[C(R³)₂]_n-N(R²)₂, NO₂, CN, -[C(R³)₂]_n-COOR², -[C(R³)₂]_n-CON(R²)₂, -[C(R³)₂]_n-NR²COA, NR²CON(R²)₂, -[C(R³)₂]_n-NR²SO₂A, COR², SO₂NR² and/or S(O)_mA,

Het¹ is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, =S, =N(R³)₂, Hal, A, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²CON(R²)₂, NR²SO₂A, COR², SO₂NR² and/or S(O)_mA,

Hal is F, Cl, Br or I,

n is 0, 1 or 2,

m is 0, 1 or 2,

o is 1, 2 or 3, or

a pharmaceutically usable derivative, solvate, or stereoisomer thereof, including mixtures thereof in all ratios.

2. (Previously Presented): A compound according to Claim 1, in which D is absent.

3. (Previously Presented): A compound according to Claim 1, in which M is a phenyl ring.

4. (Previously Presented): A compound according to Claim 1, in which D is a saturated, fully or partially unsaturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O and/or 1 or 2 S atoms, but where at most up to 3 carbon atoms are replaced and where, in addition, the alkylene chain and/or a nitrogen present therein may be monosubstituted, disubstituted or trisubstituted by Hal, A, OR² or N(R²)₂, and where, furthermore, one CH₂ group in the alkylene chain may also be replaced by a C=O group.

5. (Previously Presented): A compound according to Claim 1, in which D is a saturated, fully or partially unsaturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O

and/or 1 or 2 S atoms, but where at most up to 3 carbon atoms are replaced and where, in addition, the alkylene chain and/or a nitrogen present therein may be monosubstituted, disubstituted or trisubstituted by A or NH₂.

6. (Previously Presented): A compound according to Claim 1, in which D is absent or is a saturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O atoms, but where at most up to 3 carbon atoms are replaced, and where, in addition, the alkylene chain and/or a nitrogen atom located therein is unsubstituted, or monosubstituted or disubstituted by NH₂.

7. (Previously Presented): A compound according to Claim 1, in which D is absent or is -CH=N-CH=CH-, -CH=CH-N=CH-, -NH-N=CH-, -CH=N-NH-, -O-N=CH- or -CH=N-O-, and where, in addition, D is unsubstituted or monosubstituted by NH₂.

8. (Previously Presented): A compound according to Claim 1, in which R¹ is H, -[C(R³)₂]_n-N(R³)₂, CON(R²)₂, C(=S)NH₂ or N(R²)₂, and R^{1'} is H.

9. (Previously Presented): A compound according to Claim 1, in which R¹ is H, CH₂NH₂, CONH₂, C(=S)NH₂ or NH₂, and R^{1'} is H.

10. (Previously Presented): A compound according to Claim 1, in which W is a monocyclic saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be monosubstituted or disubstituted by R².

11. (Previously Presented): A compound according to Claim 1, in which W is cyclohexanediyI, cyclopentanediyI, phenylene, biphenylene, furandiyI, thiophenediyI, pyrrolediyI, imidazolediyI, pyrazolediyI, oxazolediyI, isoxazolediyI, thiazolediyI,

isothiazolediyl, pyridinediyl, pyrimidinediyl, pyrrolidinediyl, piperidinediyl or piperazinediyl, each of which is unsubstituted or monosubstituted or disubstituted by R².

12. (Previously Presented): A compound according to Claim 1, in which W is pyrazolediyl, which is unsubstituted or monosubstituted by A.

13. (Previously Presented): A compound according to Claim 1, in which X is CONH, CONHCH₂, CH₂NH or CH₂NHCH₂.

14. (Previously Presented): A compound according to Claim 1, in which X is CONH.

15. (Previously Presented): A compound according to Claim 1, in which Y is alkylene or Ar-diyl.

16. (Previously Presented): A compound according to Claim 1, in which Y is phenylene which is unsubstituted or monosubstituted or disubstituted by A, Br, Cl or F.

17. (Previously Presented): A compound according to Claim 1, in which T is a monocyclic saturated or unsaturated heterocyclic ring having from 1 to 3 N, O and/or S atoms, which is monosubstituted or disubstituted by =S, =NR², =NOR², =N-CN, =N-NO₂, =NCOR², =NCOOR² or =NOCOR², which is unsubstituted or monosubstituted or disubstituted by A, CON(R²)₂ or COOR².

18. (Previously Presented): A compound according to Claim 1, in which T is a monocyclic saturated or unsaturated heterocyclic ring having from 1 to 3 N, O and/or S atoms, which is monosubstituted or disubstituted by =S, =NR², =N-CN or =NOR², which is unsubstituted or monosubstituted or disubstituted by A, CON(R²)₂ or COOR².

19. (Previously Presented): A compound according to Claim 1, in which T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-

oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, imidazolidin-1-yl, 1,3,4-thiadiazol-3-yl or 1,2-dihdropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR², =S, =N-CN or =NOR² and may furthermore be monosubstituted or disubstituted by A, CONH₂ or COOA.

20. (Previously Presented): A compound according to Claim 1, in which T is 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 2-imino-1*H*-pyridin-1-yl, 3-iminomorpholin-4-yl, 4-imino-1*H*-pyridin-1-yl, 2,6-diiminopiperidin-1-yl, 2-iminopiperazin-1-yl, 2,6-diiminopiperazin-1-yl, 2,5-diiminopyrrolidin-1-yl, 2-imino-1,3-oxazolidin-3-yl, 3-imino-2*H*-pyridazin-2-yl, 2-iminoazepan-1-yl, 2-hydroxy-6-iminopiperazin-1-yl, pyrazol-2-yl, 1,2-dihdropyrazol-2-yl, 2-methoxy-6-iminopiperazin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl, and the corresponding hydroxyimino, alkoxyimino, thioxo and =N-(CH₂)₁₋₃NA' derivatives, where A' is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, and where the heterocyclic rings are unsubstituted or monosubstituted or disubstituted by A, CONH₂ or COOA.

21. (Previously Presented): A compound according to Claim 1, in which T is 2-iminopyrrolidin-1-yl, 2-iminopiperidin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl or 3-imino-1,2-dihdropyrazol-2-yl, and the corresponding hydroxyimino, alkoxyimino and thioxo derivatives, where the heterocyclic radicals are in each case unsubstituted or monosubstituted or disubstituted by A, CONH₂ or COOA.

22. (Previously Presented): A compound according to Claim 1, in which D is absent or is -CH=N-CH=CH-, -CH=CH-N=CH-, -NH-N=CH-, -CH=N-NH-, -O-N=CH- or -CH=N-O-, M is a phenyl ring, R¹ is H, CH₂NH₂, CONH₂, C(=S)NH₂ or NH₂, R^{1'} is H, W is a monocyclic saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be monosubstituted or disubstituted by R²,

R^2 is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
 $R^{2'}$ is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
 X is CONH, CONHCH₂, CH₂NH or CH₂NHCH₂,
 Y is alkylene or Ar-diyl,
 Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OH, NH₂, NO₂, CN, COOH, CONH₂, NHCOA, NHCONH₂, NHSO₂A, COH, SO₂NH₂, S(O)_mA, -(CH₂)_n-COOR² or -O-(CH₂)_o-COOR^{2'},
m and n are each, independently of one another, 0, 1 or 2,
o is 1, 2 or 3, and
 T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, 1,3,4-thiadiazol-3-yl, imidazolidin-1-yl or 1,2-dihydropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and may furthermore be monosubstituted or disubstituted by A, CONH₂ or COOA.

23. (Previously Presented): A compound according to Claim 1, in which
 D is absent or is -CH=N-CH=CH-, -CH=CH-N=CH-, -NH-N=CH-, -CH=N-NH-, -O-N=CH- or -CH=N-O-,
 M is a phenyl ring,
 R^1 is H, CH₂NH₂, CONH₂, C(=S)NH₂ or NH₂,
 $R^{1'}$ is H,
 W is cyclohexanediyl, cyclopentanediyl, phenylene, biphenylene, furandiyl, thiophenediyl, pyrrolediyl, imidazolediyl, pyrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl, isothiazolediyl, pyridinediyl, pyrimidinediyl or pyrrolidinediyl, each of which is unsubstituted or monosubstituted or disubstituted by R^2 ,
 R^2 is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
 $R^{2'}$ is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
 X is CONH, CONHCH₂, CH₂NH or CH₂NHCH₂,
 Y is phenylene which is unsubstituted or monosubstituted or disubstituted by A, Br, Cl or F,

A is unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms and/or in addition 1-7 H atoms may be replaced by F, and

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, 1,3,4-thiadiazol-3-yl, imidazolidin-1-yl or 1,2-dihdropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and may furthermore be monosubstituted or disubstituted by A, CONH₂ or COOA.

24. (Previously Presented): A compound I according to Claim 1, in which

D is absent or is -CH=N-CH=CH-, -CH=CH-N=CH-, -NH-N=CH-, -CH=N-NH-, -O-N=CH- or -CH=N-O-,

M is a phenyl ring,

R¹ is H, CH₂NH₂, CONH₂, C(=S)NH₂ or NH₂,

R^{1'} is H,

W is pyrazolediyl or thiazolediyl, each of which is unsubstituted or monosubstituted by A,

X is CONH,

Y is phenylene which is unsubstituted or monosubstituted or disubstituted by A, Br, Cl or F, and

T is 2-iminopyrrolidin-1-yl, 2-iminopiperidin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl or 3-imino-1,2-dihdropyrazol-2-yl, and the corresponding hydroxyimino, cyanoimino, alkoxyimino and thioxo derivatives, where the heterocyclic radicals are in each case unsubstituted or monosubstituted or disubstituted by A, CONH₂ or COOA,

A is unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms and/or in addition 1-7 H atoms may be replaced by F.

25. (Previously Presented): A compound according to Claim 1 selected from the group consisting of:

N-[4-(2-iminopyrrolidin-1-yl)phenyl]-2-(3-aminomethylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-thioxopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-iminopyrrolidin-1-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-imino-5-methyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(1,5-dimethyl-3-imino-1,2-dihdropyrazol-2-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-thioxopyrrolidin-1-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-amino-1*H*-indazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-thioxopyrrolidin-1-yl)phenyl]-2-(3-amino-1*H*-indazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-thiocarbamoylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-hydroxyiminopyrrolidin-1-yl)phenyl]-2-(3-aminomethylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[3-methyl-4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-iminopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[3-bromo-4-(2-imino-5-methyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-imino-5-methyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-iminoimidazolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,


N-[4-(2-iminoimidazolidin-1-yl)-3-methylphenyl]-2-(3-aminocarbonylphenyl)-5-

trifluoromethyl-2*H*-pyrazole-3-carboxamide,
 N-[4-(2-cyanoiminoimidazolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
 N-[4-(2-cyanoimino-3-methylimidazolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
 N-[4-(2-imino-5-ethyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
 N-[4-(2-imino-5-aminocarbonyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
 N-[4-(2-imino-5-ethoxycarbonyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
 N-[4-(2-imino-5-ethyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-5-(3-aminocarbonylphenyl)-2-methylthiazole-4-carboxamide,
 N-[4-(2-imino-5-ethyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-methyl-2*H*-pyrazole-3-carboxamide,
 and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

26. (Previously Presented): A process for the preparation a compound according to Claim 1, said process comprising:

a) for the preparation of a compound in which X is CONR² or CONR²C(R³)₂,


a compound of the formula II



in which

L is Cl, Br, I or a free or reactively functionally modified OH group,
 with the proviso that any further OH and/or amino group present is protected,

is reacted with a compound of the formula III



in which

Z' is NHR^2 or $\text{NHR}^2\text{C}(\text{R}^3)_2$,
and R^2 , Y and T are as defined in Claim 1,
and any protecting group is subsequently removed,

b) and/or in that a radical T , R^1 and/or R^1' is converted into another radical T , R^1 and/or R^1'

by,

- i) converting a sulfanyl compound into an imino compound,
- ii) removing an amino-protecting group,

and/or

a base or acid of the formula I is converted into one of its salts.

27. (Previously Presented): A method of inhibiting coagulation factor Xa in a patient, comprising administering to said patient a compound according to Claim 1.

28. (Previously Presented): A method of inhibiting coagulation factor VIIa in a patient, comprising administering to said patient a compound according to Claim 1.

29. (Previously Presented): A pharmaceutical composition comprising a compound according to Claim 1 and at least one excipient and/or adjuvant.

30. (Previously Presented): A pharmaceutical composition according to Claim 29, further comprising at least one further medicament active ingredient.

31. (Previously Presented): A method for treating thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases in a patient, comprising administering to said patient a compound according to claim 1.

32. (Previously Presented): A kit consisting of separate packs of
(a) an effective amount of a compound according to Claim 1, and
(b) an effective amount of a further medicament active ingredient.

33. (Previously Presented): A method according to claim 31, further comprising administering to said patient at least one further medicament active ingredient.

34. (Previously Presented): A compound according to claim 1, wherein
D is absent,
M is phenyl,
W is pyrazolediyl which is unsubstituted or monosubstituted or disubstituted by A,
CONH₂ or COOA,
X is CONH,
Y is Ar-diyl,
Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OH, NH₂, NO₂, CN, COOH, CONH₂, NHCOA, NHCONH₂, NHSO₂A, COH,
SO₂NH₂, S(O)_mA, -(CH₂)_n-COOR² or -O-(CH₂)_o-COOR², and
T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl,
1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl,
1,3,4-thiadiazol-3-yl, imidazolidin-1-yl or 1,2-dihydropyrazol-2-yl, each of which is
monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and may furthermore be
monosubstituted or disubstituted by A, CONH₂ or COOA.

35. (Previously Presented): A compound according to claim 34, wherein T is
2-iminopyrrolidin-1-yl, 2-iminopiperidin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl,
2-iminoimidazolidin-1-yl, 3-imino-1,2-dihydropyrazol-2-yl, 2-hydroxyiminopyrrolidin-1-yl,

2-hydroxyiminopiperidin-1-yl, 2-hydroxyimino-1,3,4-thiadiazol-3-yl,
2-hydroxyiminoimidazolidin-1-yl, 3-hydroxyimino-1,2-dihydropyrazol-2-yl,
2-thioxopyrrolidin-1-yl, 2-thioxopiperidin-1-yl, 2-thioxo-1,3,4-thiadiazol-3-yl,
2-thioxoimidazolidin-1-yl, or 3-thioxo-1,2-dihydropyrazol-2-yl.

36. (Previously Presented): A compound according to claim 34, wherein T is pyrrolidin-1-yl or 1,3,4-thiadiazol-3-yl which in each case is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and is further optionally monosubstituted or disubstituted by A, CONH₂ or COOA.

37. (Previously Presented): A compound according to claim 36, wherein T is pyrrolidin-1-yl which is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and is further optionally monosubstituted or disubstituted by A, CONH₂ or COOA.

38. (Previously Presented): A compound according to claim 36, wherein T is 1,3,4-thiadiazol-3-yl which is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and is further optionally monosubstituted or disubstituted by A, CONH₂ or COOA.

39. (Previously Presented): A compound according to Claim 34, wherein R¹ is H, -[C(R³)₂]_n-N(R³)₂, CON(R²)₂, C(=S)NH₂ or N(R²)₂, and R^{1'} is H.

40. (Previously Presented): A compound according to Claim 39, wherein R¹ is H, CH₂NH₂, CONH₂, C(=S)NH₂ or NH₂.

41. (Previously Presented): A compound according to Claim 35, wherein R¹ is H, -[C(R³)₂]_n-N(R³)₂, CON(R²)₂, C(=S)NH₂ or N(R²)₂, and R^{1'} is H.

42. (Previously Presented): A compound according to Claim 41, wherein R¹ is H, CH₂NH₂, CONH₂, C(=S)NH₂ or NH₂.

43. (Previously Presented): A compound according to Claim 37, wherein
 R^1 is H, $-(C(R^3)_2)_n-N(R^3)_2$, $CON(R^2)_2$, $C(=S)NH_2$ or $N(R^2)_2$, and
 $R^{1'}$ is H.

44. (Previously Presented): A compound according to Claim 43, wherein R^1 is H, CH_2NH_2 , $CONH_2$, $C(=S)NH_2$ or NH_2 .

45. (New): A compound according to Claim 1, wherein
D is absent,
M is a phenyl ring,
 R^1 is CH_2NH_2 ,
 $R^{1'}$ is H,
W is pyrazolediyl which is unsubstituted or monosubstituted by R^2 , and
X is $CONH$.

46. (New): A compound according to Claim 1, wherein
 R^1 is H, CH_2NH_2 , $CONH_2$, $C(=S)NH_2$ or NH_2 ,
 $R^{1'}$ is H,
 R^2 is trifluoromethyl,
W is pyrazolediyl which is unsubstituted or monosubstituted by R^2
X is $CONH$, and
D is absent and M is phenyl, or D and M together are benzo[d]isoxazol-5-yl or 1*H*-indazol-5-yl.

47. (New): A compound according to Claim 1, wherein W is pyrazolediyl which is unsubstituted or monosubstituted by R^2 .

48. (New): A compound according to Claim 47, in which M is a phenyl ring.

49. (New): A method of treating thromboses in a patient comprising administering to said patient a compound according to claim 1.

50. (New): A method of treating myocardial infarction in a patient comprising administering to said patient a compound according to claim 1.

51. (New): A method of treating arteriosclerosis in a patient comprising administering to said patient a compound according to claim 1.

52. (New): A method of treating inflammation in a patient, comprising administering to said patient a compound according to claim 1.

53. (New): A method of treating apoplexia in a patient comprising administering to said patient a compound according to claim 1.

54. (New): A method of treating angina pectoris in a patient comprising administering to said patient a compound according to claim 1.

55. (New): A method of treating restenosis after angioplasty in a patient comprising administering to said patient a compound according to claim 1.

56. (New): A method of treating claudicatio intermittens in a patient comprising administering to said patient a compound according to claim 1.

57. (New): A method of treating migraine in a patient comprising administering to said patient a compound according to claim 1.

58. (New): A method of treating a patient suffering from a thromboembolic disease comprising administering to said patient a compound according to claim 1.